Selected article for: "acute sars respiratory syndrome and live market"

Author: Rabi, Firas A.; Al Zoubi, Mazhar S.; Kasasbeh, Ghena A.; Salameh, Dunia M.; Al-Nasser, Amjad D.
Title: SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far
  • Cord-id: ifoe8x28
  • Document date: 2020_3_20
  • ID: ifoe8x28
    Snippet: In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrom
    Document: In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes.

    Search related documents:
    Co phrase search for related documents
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and low respiratory tract: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung type ii pneumocyte: 1, 2
    • additional benefit and lopinavir ritonavir: 1, 2
    • additional benefit and lung cancer: 1, 2
    • adenosine analog and lopinavir ritonavir: 1
    • long distance and lopinavir ritonavir: 1, 2
    • lopinavir ritonavir and low respiratory tract: 1
    • lopinavir ritonavir and lung cancer: 1, 2, 3